Ann Dermatol.
2023 Nov;35(Suppl2):S373-S375. 10.5021/ad.22.055.
Local Recurrent Melanoma Treated with BRAF and MEK Inhibitors Despite Adjuvant Anti-Programmed Cell Death Protein 1 Antibody Therapy
- Affiliations
-
- 1Department of Dermatology, Inha University School of Medicine, Incheon, Korea
- KMID: 2548933
- DOI: http://doi.org/10.5021/ad.22.055
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
- Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
- Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition
- A Case of Anti-programmed Cell Death Ligand 1 and Anti-transforming Growth Factor Beta Antibody-associated Keratoacanthoma
- Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review
